P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial.
Saved in:
| Title: | P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial. |
|---|---|
| Authors: | Fernández Montes, A.1 (AUTHOR), Martinez Lago, N.2 (AUTHOR), De la Cámara Gómez, J.3 (AUTHOR), Covela Rúa, M.4 (AUTHOR), Cousillas Castiñeiras, A.5 (AUTHOR), Gonzalez Villarroel, P.6 (AUTHOR), Méndez Méndez, J.7 (AUTHOR) |
| Source: | Annals of Oncology. 2019 Supplement, Vol. 30, piv23-iv24. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 152694201 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Fernández+Montes%2C+A%2E%22">Fernández Montes, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martinez+Lago%2C+N%2E%22">Martinez Lago, N.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+la+Cámara+Gómez%2C+J%2E%22">De la Cámara Gómez, J.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Covela+Rúa%2C+M%2E%22">Covela Rúa, M.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cousillas+Castiñeiras%2C+A%2E%22">Cousillas Castiñeiras, A.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gonzalez+Villarroel%2C+P%2E%22">Gonzalez Villarroel, P.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Méndez+Méndez%2C+J%2E%22">Méndez Méndez, J.</searchLink><relatesTo>7</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2019 Supplement, Vol. 30, piv23-iv24. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152694201 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/annonc/mdz155.088 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: iv23 Titles: – TitleFull: P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fernández Montes, A. – PersonEntity: Name: NameFull: Martinez Lago, N. – PersonEntity: Name: NameFull: De la Cámara Gómez, J. – PersonEntity: Name: NameFull: Covela Rúa, M. – PersonEntity: Name: NameFull: Cousillas Castiñeiras, A. – PersonEntity: Name: NameFull: Gonzalez Villarroel, P. – PersonEntity: Name: NameFull: Méndez Méndez, J. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 07 Text: 2019 Supplement Type: published Y: 2019 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 30 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
